Compare Endeavour Silver Corp (EXK) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Natera Inc. Common Stock — how do they compare? Endeavour Silver Corp trades at $7.9 (market cap $2.44B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 23.4× Endeavour Silver Corp's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 26 Days and Natera Inc. Common Stock for 0 Days on average.
| EXK | NTRA | |
|---|---|---|
Market Cap | $2.44B | $57.03B |
Volume | 5,983,279 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $425.64 |
52-Week Low | $7.07 | $179.42 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $2.44B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.24, down 3.51% on the day, amid a bearish technical signal with moving averages indicating selling pressure. The company reported a net loss of $119.1 million in 2025 but improved to a net profit of $66 million in 2026, driven by revenue growth from $468 million to $737 million. Recent news highlights operational progress at the Terronera mine and a temporary mechanical issue at Guanacevi, while analyst consensus remains strongly positive with 11 buy ratings.
The outlook for EXK hinges on successful execution of mine expansions and favorable silver prices, offering growth potential, but risks include operational disruptions, commodity price volatility, and high valuation multiples. Investors should weigh the strong analyst support against near-term profitability challenges and market sentiment.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
